2 recruiting, 1 active not recruiting, 1 not yet recruiting. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Recruiting 1 |
Follow Guselkumab (GUS): new trials by email Literature Review of Guselkumab (GUS) trials Research Report on Guselkumab (GUS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease Guselkumab (GUS), Risankizumab (RISA) - Psoriasis, Psoriasis Arthritis | Not yet recruiting | Caja Costarricense de Seguro Social | 50 | 2026-05-01 | 2026-03-09 | |
| Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease Guselkumab (GUS), Ustekinumab (UST) - CD - Crohn's Disease, Stricture; Bowel | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2026-03-01 | 2026-03-02 | |
| A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) Guselkumab (GUS) - Crohn Disease | Phase 4 | Recruiting | Xian-Janssen Pharmaceutical Ltd. | 78 | 2025-12-30 | 2026-09-25 |
| VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study Vedolizumab (VDZ), Ustekinumab (UST), Risankizumab (RISA) - Crohn's Disease | Active not recruiting | Alimentiv Inc. | 300 | 2024-03-20 | 2026-08-21 |
Crohn Disease (3) · Constriction, Pathologic (1) · Inflammatory Bowel Diseases (1) · Psoriasis (1)
Alimentiv Inc. (1) · Caja Costarricense de Seguro Social (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Xian-Janssen Pharmaceutical Ltd. (1)
China (2) · Canada (1) · Costa Rica (1) · United States (1)